160 related articles for article (PubMed ID: 38878446)
21. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
[TBL] [Abstract][Full Text] [Related]
23. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
[TBL] [Abstract][Full Text] [Related]
24. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review.
Zhu L; Xu R; Yang L; Shi W; Zhang Y; Liu J; Li X; Zhou J; Bing P
Front Genet; 2023; 14():1172108. PubMed ID: 37636270
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I-IV colorectal cancer.
Fan W; Xia Z; Chen R; Lin D; Li F; Zheng Y; Luo J; Xiong Y; Yu P; Gao W; Gong Y; Zhang F; Zhang S; Li L
Ther Adv Med Oncol; 2024; 16():17588359231220607. PubMed ID: 38282662
[TBL] [Abstract][Full Text] [Related]
27. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
28. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).
Folprecht G; Reinacher-Schick A; Weitz J; Lugnier C; Kraeft AL; Wisser S; Aust DE; Weiss L; von Bubnoff N; Kramer M; Thiede C; Tannapfel A
Clin Colorectal Cancer; 2022 Jun; 21(2):170-174. PubMed ID: 34772609
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer.
Fang X; Yu S; Jiang Y; Xiang Y; Lu K
Front Oncol; 2022; 12():1027664. PubMed ID: 36387176
[TBL] [Abstract][Full Text] [Related]
30. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
31. Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer.
Tian X; Liu X; Wang K; Wang R; Li Y; Qian K; Wang T; Zhao X; Liu L; Zhang PL; Xiong Y; Rui J; Chen R; Zhang Y
Thorac Cancer; 2024 Apr; 15(10):797-807. PubMed ID: 38409945
[TBL] [Abstract][Full Text] [Related]
32. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
33. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives.
Merk C; Martling A; Lindberg J; Benhaim L; Taieb J; Lind P
Acta Oncol; 2022 Apr; 61(4):523-530. PubMed ID: 35139729
[TBL] [Abstract][Full Text] [Related]
35. Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer.
Olivier T; Haslam A; Prasad V
BMC Med; 2023 Sep; 21(1):344. PubMed ID: 37679732
[TBL] [Abstract][Full Text] [Related]
36. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study).
Chen Y; Zhang J; Han G; Tang J; Guo F; Li W; Xie L; Xu H; Zhang X; Tian Y; Pan L; Shu Y; Ma L; Chen X
Front Immunol; 2023; 14():1232858. PubMed ID: 38022553
[TBL] [Abstract][Full Text] [Related]
38. Applications of Liquid Biopsy for Surgical Patients With Cancer: A Review.
Mahuron KM; Fong Y
JAMA Surg; 2024 Jan; 159(1):96-103. PubMed ID: 37910091
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor DNA analysis guiding adjuvant treatment in resected stage III cholangiocarcinoma: a case report.
Yu J; Avriett TA; Ray CM; Kim RD
J Gastrointest Oncol; 2024 Feb; 15(1):485-490. PubMed ID: 38482231
[TBL] [Abstract][Full Text] [Related]
40. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
